VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Sheri L. Rowen, MD, discusses new ...

The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...

The Food and Drug Administration has approved the first aceclidine-based eye drop designed to improve near vision in adults with presbyopia. This age-related condition affects more than 100 million ...

LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater ...

In a significant move to enhance brand visibility and outreach, Lenz Therapeutics has launched its 'Make It Vizzable' campaign, featuring renowned actress and produc ...

Sarah Jessica Parker fronts LENZ Therapeutics’ “Make It VIZZable” campaign, raising awareness of presbyopia and spotlighting ...

Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related ...

Welcome to the health and wellness podcast. In this episode, we are joined by Irene Gitonga, an optometrist, to discuss the causes, symptoms, and treatment of presbyopia. Tune in to listen.